FDA-cleared profile

Radiation Planning Assistant (RPA)

University of Texas, MD Anderson Cancer Center

Radiation Planning Assistant creates initial CT-based contours and photon external-beam treatment plans for head-and-neck, cervical, breast, and whole-brain radiotherapy; every result must be imported into the user's treatment-planning system for review, editing, and final dose calculation.

Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.

Product overview

Start with the essentials

Radiation Planning Assistant creates initial CT-based contours and photon external-beam treatment plans for head-and-neck, cervical, breast, and whole-brain radiotherapy; every result must be imported into the user's treatment-planning system for review, editing, and final dose calculation.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Clinical details

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Radiation Planning Assistant creates initial CT-based contours and photon external-beam treatment plans for head-and-neck, cervical, breast, and whole-brain radiotherapy; every result must be imported into the user's treatment-planning system for review, editing, and final dose calculation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Intended users
Value withdrawn pending re-verification
  • Corrected record
  • Exact FDA submission
  • Checked 2026-09-19

Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.

Care setting and population
Radiation-oncology departments, including resource-constrained clinics able to support the required CT and treatment-planning workflow.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Workflow role
Automated contouring, plan generation, dose optimization, and quality-control support before independent TPS review and calculation.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Radiotherapy planning CT images and required clinical planning inputs.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and human action
Initial contours and external-beam photon plans for import into the user's treatment-planning system.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
RPA is not a primary treatment-planning system. Every contour and plan must be imported into the user's TPS for review, editing, and final dose calculation; unsupported disease sites, techniques, machines, or local protocols must not be inferred.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K222728
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-05-17
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Uses some Eclipse 15.6 functions and exports contours and plans to the user's TPS; validate DICOM transfer, structure naming, beam model, machine configuration, dose recalculation, plan integrity, and failure recovery.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Deployment and data flow
Web-based planning software with site-specific integration to CT, network, and treatment-planning infrastructure; current no-cost access goals are product-family context, not a guaranteed commercial term.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Security and privacy
Vendor documentation pending
  • Vendor confirmation
  • Exact FDA submission
  • Checked 2026-09-03

Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.

Training and support
Only qualified radiation oncologists, medical physicists, dosimetrists, and trained radiation-therapy planning staff. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring and change control
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: RPA is not a primary treatment-planning system. Every contour and plan must be imported into the user's TPS for review, editing, and final dose calculation; unsupported disease sites, techniques, machines, or local protocols must not be inferred.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K222728 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Uses some Eclipse 15.6 functions and exports contours and plans to the user's TPS; validate DICOM transfer, structure naming, beam model, machine configuration, dose recalculation, plan integrity, and failure recovery.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. RPA is not a primary treatment-planning system. Every contour and plan must be imported into the user's TPS for review, editing, and final dose calculation; unsupported disease sites, techniques, machines, or local protocols must not be inferred.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: RPA is not a primary treatment-planning system. Every contour and plan must be imported into the user's TPS for review, editing, and final dose calculation; unsupported disease sites, techniques, machines, or local protocols must not be inferred.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K222728 describes large training sets and multicenter performance testing at five sites using Philips, Siemens, and GE CT data. Site-specific tests covered cervical, chest-wall, head-and-neck, and whole-brain planning, with explicit contour, dosimetry, isocenter, and plan-review criteria plus documented cervical VMAT exceptions requiring careful local acceptance.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Clinical evaluation sites

5 sites

  • EndpointMulticenter planning evaluation
  • PopulationRadiation Planning Assistant (RPA)
  • Tested versionRadiation Planning Assistant release cleared in K222728

Head-and-neck evaluation patients

86 patients

  • EndpointRPA head-and-neck plan evaluation
  • PopulationRadiation Planning Assistant (RPA)
  • Tested versionRadiation Planning Assistant release cleared in K222728

Cervix VMAT evaluation patients

50 patients

  • EndpointRPA cervical VMAT plan evaluation
  • PopulationRadiation Planning Assistant (RPA)
  • Tested versionRadiation Planning Assistant release cleared in K222728

Cervix surface Dice criterion

0.8 DSC

  • EndpointBody contours within 2 mm for 95% of CT scans
  • PopulationRadiation Planning Assistant (RPA)
  • Tested versionRadiation Planning Assistant release cleared in K222728

Cervix isocenter criterion

3 mm

  • EndpointAgreement in all orthogonal directions for 95% of cases
  • PopulationRadiation Planning Assistant (RPA)
  • Tested versionRadiation Planning Assistant release cleared in K222728

K222728 FDA performance package for Radiation Planning Assistant (RPA)

  • DesignManufacturer multicenter external evaluation of automated contours and treatment plans against clinical contours, plans, and dosimetric criteria
  • PopulationCervical, post-mastectomy chest-wall, head-and-neck, and whole-brain radiotherapy cases from five clinical sites
  • Scopeexact submission
  • Tested versionRadiation Planning Assistant release cleared in K222728
  • Sites5
  • IndependenceSponsor or vendor study

K222728

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Costs and setup

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-03

No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Public source
  • Not applicable
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K222728 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
26Fields reviewed
9Source classes checked
20Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 20 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, pubmed, clinical trials, openfda device recall

Sources & history

How this profile was documented

Open the ledger for source dates, scope, and research-record updates.

View source ledger and history

Source ledger

  1. FDA K222728: Radiation Planning Assistant (RPA)

    U.S. Food and Drug Administration - Published 2023-05-17 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Radiation Planning Assistant

    The University of Texas MD Anderson Cancer Center - Accessed 2026-09-03

    Scope: productFamily, workflowRole, deployment, implementationCapabilities, currentCommercialContext

Research history

  1. K222728 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K253091

ART-Plan+ (v3.1.0)

Therapanacea Sas

ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091....

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K241490

Contour+ (MVision AI Segmentation)

MVision AI Oy

Contour+ generates initial CT and MR anatomical contours across head and neck, brain, breast, thoracoabdominal, and pelvic radiation-treatment planning workflows for qualified...

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2024-10-18
FDA-cleared K260509

AutoContour (RADAC V5)

Radformation, Inc.

AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces...

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-03-19